Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function
NCT06038630Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hyperpolarized xenon gas in interstitial lung disease (ILD), chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary embolism (PE) and 3 more (3 arms). Primary endpoints: Change in RBC to Membrane Ratio Pre and Post Transfusion or Apheresis, Change in RBC Chemical Shift After Oxygen Administration at 1 day and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
interstitial lung disease (ILD)chronic thromboembolic pulmonary hypertension (CTEPH)pulmonary embolism (PE)anemiapolycythemia vera (PV)
Beyond the preview
Go deeper on NCT06038630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038630.